On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression
Abstract Results from a recent Phase II trial of psilocybin-assisted therapy for treatment-resistant depression suggest modest efficacy but raise concerns about potential for serious adverse effects.